Business
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference. A live webcast of the event will be accessible both here and on MediW
About this update from Mediwound Ltd.
[{"type":"image","alt":"MediWound Ltd.","displaySize":"","headline":null,"caption":"MediWound Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lMBSATvDCuA9PnawJVvewQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159","width":300,"height":113}},"lazy":false},{"type":"text","content":"YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference.","length":430,"tagName":"p"},{"type":"text","content":"A live webcast of the event will be accessible both here and on MediWound’s website, under the Events & Presentations page of the Investors section.","length":152,"tagName":"p"},{"type":"text","content":"About MediWound ","length":15,"tagName":"p"},{"type":"text","content":"MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.","length":617,"tagName":"p"},{"type":"text","content":"For more information visit www.mediwound.com and follow us on LinkedIn.","length":86,"tagName":"p"},{"type":"text","content":"MediWound Contacts: ...